NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance

Xiaoguang Li, Zhida Liu, Anli Zhang, Chuanhui Han, Aijun Shen, Lingxiang Jiang, David A Boothman, Jian Qiao, Yang Wang, Xiumei Huang, Yang-Xin Fu

Research output: Contribution to journalArticle

Abstract

Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1high tumor cells triggering oxidative stress and release of the damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.

Original languageEnglish (US)
Article number3251
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Prodrugs
Tumors
tumors
actuators
Neoplasms
T-cells
Tumor Microenvironment
T-Lymphocytes
Immunotherapy
Cross-Priming
Interferon Type I
interferon
Adaptive Immunity
priming
Innate Immunity
NAD
Dendritic Cells
Oxidative stress
quinones
Oxidoreductases

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. / Li, Xiaoguang; Liu, Zhida; Zhang, Anli; Han, Chuanhui; Shen, Aijun; Jiang, Lingxiang; Boothman, David A; Qiao, Jian; Wang, Yang; Huang, Xiumei; Fu, Yang-Xin.

In: Nature communications, Vol. 10, No. 1, 3251, 01.12.2019.

Research output: Contribution to journalArticle

Li, Xiaoguang ; Liu, Zhida ; Zhang, Anli ; Han, Chuanhui ; Shen, Aijun ; Jiang, Lingxiang ; Boothman, David A ; Qiao, Jian ; Wang, Yang ; Huang, Xiumei ; Fu, Yang-Xin. / NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{a3ebb2476d33463089625e2593f9068c,
title = "NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance",
abstract = "Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1high tumor cells triggering oxidative stress and release of the damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.",
author = "Xiaoguang Li and Zhida Liu and Anli Zhang and Chuanhui Han and Aijun Shen and Lingxiang Jiang and Boothman, {David A} and Jian Qiao and Yang Wang and Xiumei Huang and Yang-Xin Fu",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-11238-1",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance

AU - Li, Xiaoguang

AU - Liu, Zhida

AU - Zhang, Anli

AU - Han, Chuanhui

AU - Shen, Aijun

AU - Jiang, Lingxiang

AU - Boothman, David A

AU - Qiao, Jian

AU - Wang, Yang

AU - Huang, Xiumei

AU - Fu, Yang-Xin

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1high tumor cells triggering oxidative stress and release of the damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.

AB - Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1high tumor cells triggering oxidative stress and release of the damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.

UR - http://www.scopus.com/inward/record.url?scp=85069469222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069469222&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-11238-1

DO - 10.1038/s41467-019-11238-1

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 3251

ER -